行情

CLSN

CLSN

Celsion
NASDAQ

实时行情|Nasdaq Last Sale

1.750
0.000
0.00%
已收盘, 16:00 09/17 EDT
开盘
1.750
昨收
1.750
最高
1.800
最低
1.750
成交量
8.16万
成交额
--
52周最高
2.880
52周最低
1.350
市值
3,742.80万
市盈率(TTM)
-4.7632
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CLSN 新闻

  • 美国国务卿蓬佩奥谴责伊朗袭击沙特油田
  • 央视.2天前
  • 在美国腐败调查的阴影下 UAW和通用汽车接近合同期限
  • 新浪美股.2天前
  • 马斯克强调物流速度:亚马逊要像特斯拉一样早破产了
  • 新浪美股.2天前
  • 日韩交锋舞台转向WTO 日媒:对立或长期化
  • 参考消息.3天前

更多

所属板块

生物技术和医学研究
-0.22%
制药与医学研究
+0.42%

热门股票

名称
价格
涨跌幅

CLSN 简况

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).
展开

Webull提供Celsion Corporation的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。